104 related articles for article (PubMed ID: 2957971)
1. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
Attardo-Parrinello G; Merlini G; Pavesi F; Crema F; Fiorentini ML; Ascari E
Arch Intern Med; 1987 Sep; 147(9):1629-33. PubMed ID: 2957971
[TBL] [Abstract][Full Text] [Related]
2. Dichloromethylene diphosphonate action in hematologic and other malignancies.
Canfield RE; Siris ES; Jacobs TP
Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
[TBL] [Abstract][Full Text] [Related]
3. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
[TBL] [Abstract][Full Text] [Related]
4. Use of dichloromethylene diphosphonate in metastatic bone disease.
Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
[TBL] [Abstract][Full Text] [Related]
5. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
Siris ES; Hyman GA; Canfield RE
Am J Med; 1983 Mar; 74(3):401-6. PubMed ID: 6219577
[TBL] [Abstract][Full Text] [Related]
6. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.
Siris ES; Sherman WH; Baquiran DC; Schlatterer JP; Osserman EF; Canfield RE
N Engl J Med; 1980 Feb; 302(6):310-5. PubMed ID: 6444241
[TBL] [Abstract][Full Text] [Related]
7. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
[TBL] [Abstract][Full Text] [Related]
8. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
Chapuy MC; Charhon SA; Meunier PJ
Metab Bone Dis Relat Res; 1983; 4(6):325-8. PubMed ID: 6229683
[TBL] [Abstract][Full Text] [Related]
9. [Dichloromethylene diphosphonate (Cl2MDP) treatment of hypercalcaemia produced from bone metastases (author's transl)].
Delmas P; Chapuy MC; Vignon E; Briançon D; Charhon S; Meunier PJ
Nouv Presse Med; 1982 Apr; 11(19):1471-4. PubMed ID: 6210878
[TBL] [Abstract][Full Text] [Related]
10. Use of dichloromethylene diphosphonate in metastatic bone disease.
Jung A; van Ouwenaller C; Chantraine A; Donath A; Rosini S
N Engl J Med; 1981 Aug; 305(6):343-4. PubMed ID: 6454076
[No Abstract] [Full Text] [Related]
11. [Dichloromethylene diphosphonate in the treatment of lytic bone metastases].
Chantraine A; Jung A; van Ouwenaller C; Donath A
Presse Med; 1984 Feb; 13(8):479-82. PubMed ID: 6230629
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism.
Elomaa I; Blomqvist C; Porkka L; Holmström T; Laine H
Cancer Treat Rep; 1984 Apr; 68(4):655-7. PubMed ID: 6231989
[TBL] [Abstract][Full Text] [Related]
13. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.
Adami S; Salvagno G; Guarrera G; Bianchi G; Dorizzi R; Rosini S; Mobilio G; Lo Cascio V
J Urol; 1985 Dec; 134(6):1152-4. PubMed ID: 2932559
[TBL] [Abstract][Full Text] [Related]
14. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
[TBL] [Abstract][Full Text] [Related]
15. Clodronate for osteolytic metastases due to breast cancer.
Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH
Biomed Pharmacother; 1988; 42(2):111-6. PubMed ID: 2971403
[TBL] [Abstract][Full Text] [Related]
16. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma.
Delmas PD; Charhon S; Chapuy MC; Vignon E; Briancon D; Edouard C; Meunier PJ
Metab Bone Dis Relat Res; 1982; 4(3):163-8. PubMed ID: 6218370
[TBL] [Abstract][Full Text] [Related]
18. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.
Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Edouard C; Vignon C; Mathieu L; Trechsel U
Lancet; 1979 Sep; 2(8141):489-92. PubMed ID: 90215
[TBL] [Abstract][Full Text] [Related]
19. Treatment of bone metastases with dichloromethylene bisphosphonate.
Francini G; Gonnelli S; Petrioli R; Conti F; Paffetti P; Gennari C
J Clin Oncol; 1992 Apr; 10(4):591-8. PubMed ID: 1532198
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
